.Attributes Medicine, Released online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA confirmation after a bad trial, which highlights the various difficulties and difficulties of medicine advancement within this setup.